Merck is a lonely hunter in CETP field
One of the biggest elephants in Merck's clinic is anacetrapib. In Phase III studies that are not projected to read out until 2016/17, it sits hoovering up R&D dollars in a once-hyped cardiovascular space – CETP inhibition – that has fallen out of favor following high-profile late-stage failures at rival pharma powerhouses.